Telix Pharmaceuticals Limited announced the appointment of Dr. David Cade as Group Chief Medical Officer (CMO), effective 1 January 2024. He succeed outgoing Group CMO Dr. Colin Hayward, who has taken the decision to step down from his role effective 31 December, to pursue other interests. Dr. Cade is an experienced CMO who joined Telix in October 2019.

Prior to joining Telix David most recently served as the CMO at Cochlear Limited, and Sirtex Medical Limited, where he led numerous pivotal phase 3 oncology trials across large disease areas. During his time at Telix he has served in a range of senior executive roles and is currently Chief Executive Officer of Telix's Asia-Pacific (APAC) business 1 . He has previously served as Chief Business Officer and Head of Investor Relations at Telix.

David has led multiple strategic transactions for Telix, including the China Grand Pharma partnership, and subsequently oversaw the approval of Illuccix by the Therapeutic Goods Administration (TGA) in Australia. David brings deep experience in oncology, interventional radiology and nuclear medicine therapeutic areas. He holds a Bachelor of Medicine /Bachelor of Surgery from Monash Medical School and a Master of Business Administration from Melbourne Business School and ESADE Business and Law School.

He is also a Graduate of the Australian Institute of Company Directors.